Lantern Pharma to Demonstrate withZeta.ai AI Co-Scientist Platform in Live Public Event

Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform’s ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets.

The company said the platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model. The demonstration marks a significant milestone for Lantern as it transitions withZeta.ai from an internal research tool to a commercially available product aimed at the global biomedical and drug development community.

According to the press release, withZeta.ai is now commercially available as a subscription-based research platform, representing a new revenue stream for Lantern. The platform leverages multi-agentic AI to coordinate multiple AI agents that work together on complex tasks, enabling researchers to rapidly analyze vast datasets and generate insights that could shorten drug development cycles.

Lantern Pharma is a clinical-stage precision oncology company that uses AI and machine learning, including its proprietary RADR platform, to develop cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.

The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. For the full press release, visit https://ibn.fm/wzevl. More information about Lantern Pharma is available in the company’s newsroom at https://ibn.fm/LTRN.

The live demonstration underscores the growing importance of AI in drug discovery, particularly in oncology, where the complexity of data and the urgency of unmet medical needs drive demand for innovative solutions. By making withZeta.ai accessible via subscription, Lantern aims to democratize AI-powered research capabilities, potentially enabling smaller biotech firms and academic institutions to accelerate their own drug development programs.

Investors and industry observers will be watching the event closely to assess the platform’s capabilities and its potential to generate meaningful revenue. The demonstration could also provide insights into how Lantern plans to scale its AI offerings and compete in the rapidly evolving AI drug discovery landscape.